Transcriptomics

Dataset Information

0

FGFR4 is a regulator of tumor subtype differentiation in luminal breast cancer and metastatic disease II


ABSTRACT: Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for breast cancer therapy. We identified a subset of Luminal A primary breast tumors to give rise to HER2-enriched (HER2E) subtype metastases, but remain clinically HER2 negative (cHER2-). By testing the unique genetic and transcriptomic features of these cases, we developed the hypothesis that fibroblast growth factor receptor 4 (FGFR4) likely participates in this subtype switching. To evaluate this, we developed two FGFR4 genomic signatures using a PDX model treated with a FGFR4 inhibitor (BLU9931), which inhibited PDX growth in vivo. Bulk tumor gene expression analysis, and single cell RNAseq demonstrated that the inhibition of FGFR4 signaling caused molecular switching. Examining patient outcomes in the METABRIC breast cancer cohort showed that the FGFR4-induced and FGFR4-repressed signatures each predicted overall survival (OS) (HR=6.30, P<0.0001; HR=0.33; P<0.0001, respectively). Multivariate analysis showed that the FGFR4-induced signature was also an independent prognostic factor beyond subtype and stage for OS (HR=2.34, P=0.014). Supervised analysis of 77 primary tumors with paired metastasis revealed that the FGFR4-induced signature was significantly higher in luminal/ER+ tumor metastases compared with their primaries. Finally, multivariate analysis demonstrated that the FGFR4-induced signature also predicted site-specific metastasis for lung, liver and brain, but not for bone or lymph nodes. These data identify a link between FGFR4-regulated genes and metastasis, suggesting treatment options for FGFR4-positive patients, whose high expression is not caused by mutation or amplification.

ORGANISM(S): Homo sapiens

PROVIDER: GSE147322 | GEO | 2020/08/31

REPOSITORIES: GEO

Similar Datasets

2020-07-29 | GSE126037 | GEO
2020-07-29 | GSE126036 | GEO
2020-07-30 | GSE145326 | GEO
2020-09-22 | GSE158309 | GEO
2023-01-26 | GSE223700 | GEO
2019-05-30 | GSE124647 | GEO
2019-05-30 | GSE124648 | GEO
2008-08-22 | GSE12417 | GEO
2010-06-24 | E-GEOD-10886 | biostudies-arrayexpress
2023-07-13 | GSE235843 | GEO